10-Q: Concentra Reports Strong Q3 Growth, Expands Health Network

Concentra Group Holdings Parent, Inc. announced robust revenue growth and strategic acquisitions in its Q3 2025 report, alongside a new share repurchase program and dividend declaration.

Summary

• Revenue for the three months ended September 30, 2025, increased 17.0% to $572.8 million, compared to $489.6 million for the same period in 2024.
• Revenue for the nine months ended September 30, 2025, increased 13.2% to $1,624.3 million, compared to $1,435.2 million for the same period in 2024.
• Net income attributable to the Company for Q3 2025 was $48.3 million ($0.38 EPS), up from $44.3 million ($0.37 EPS) in Q3 2024.
• Net income attributable to the Company for the nine months ended September 30, 2025, was $131.7 million ($1.03 EPS), down from $145.0 million ($1.32 EPS) in the same period of 2024.
• Adjusted EBITDA for Q3 2025 rose 17.1% to $118.9 million (20.8% margin) from $101.6 million (20.7% margin) in Q3 2024.
• Adjusted EBITDA for the nine months ended September 30, 2025, increased 12.5% to $336.6 million (20.7% margin) from $299.3 million (20.9% margin) in the same period of 2024.
• Total patient visits increased 9.2% in Q3 2025 and 6.8% for the nine months ended September 30, 2025.
• Revenue per visit increased 4.2% in Q3 2025 and 4.7% for the nine months ended September 30, 2025.
• Acquired Nova Medical Centers for $265.0 million on March 1, 2025, adding 67 occupational health centers.
• Acquired Pivot Onsite Innovations for $54.4 million on June 1, 2025, adding over 240 onsite health clinics.
• Voluntarily repaid $50 million on the Revolving Credit Facility in Q3 2025 and an additional $35 million in October 2025, resulting in no outstanding borrowings on the facility.
• The Board of Directors authorized a $100 million share repurchase program expiring December 31, 2027.
• The Board of Directors declared a cash dividend of $0.0625 per share payable December 9, 2025.

Sentiment

Score: 8

Explanation: The company demonstrated robust revenue and Adjusted EBITDA growth, driven by successful acquisitions and increased patient volumes. Proactive debt management and a new share repurchase program are positive signals. However, increased interest expense and general and administrative costs, along with ongoing legal and regulatory challenges, temper the overall positive sentiment.

Positives

• Strong revenue growth: 17.0% for Q3 2025 and 13.2% for the nine months ended September 30, 2025.
• Increased patient volume: Total patient visits up 9.2% in Q3 2025 and 6.8% for the nine months.
• Higher revenue per visit: Up 4.2% in Q3 2025 and 4.7% for the nine months, driven by increased reimbursement rates and employer service rates.
• Strategic acquisitions: Nova Medical Centers (67 centers) and Pivot Onsite Innovations (240+ clinics) significantly expanded the company's footprint and service offerings.
• Improved staffing efficiencies: Cost of services as a percentage of revenue decreased from 71.7% to 70.8% in Q3 2025, and from 71.6% to 70.9% for the nine months.
• Strong Adjusted EBITDA growth: Up 17.1% in Q3 2025 and 12.5% for the nine months.
• Proactive debt management: Voluntary repayments of $85 million on the Revolving Credit Facility, reducing outstanding borrowings to zero.
• Shareholder returns: Authorization of a $100 million share repurchase program and declaration of a $0.0625 cash dividend.
• Effective tax rate reduction: Q3 2025 effective tax rate was 24.3% compared to 26.4% in Q3 2024. Nine months effective tax rate was 24.5% compared to 25.0% in 2024.
• Positive impact from OBBBA: $12.6 million positive impact on cash flows and cash tax position in Q3 2025 due to bonus depreciation and R&D expensing.

Negatives

• Net income attributable to the Company decreased for the nine months ended September 30, 2025, to $131.7 million ($1.03 EPS) from $145.0 million ($1.32 EPS) in the prior year, despite revenue growth.
• Increased interest expense: $28.7 million in Q3 2025 vs. $21.4 million in Q3 2024, and $82.4 million for nine months 2025 vs. $21.3 million for nine months 2024, primarily due to new debt financing.
• Higher general and administrative expenses: Increased to 9.2% of revenue in Q3 2025 (from 7.6%) and 9.4% for nine months 2025 (from 7.7%), driven by acquisition/transition costs, separation costs from Select, stock compensation, and new personnel.
• Decrease in cash: Cash balance decreased from $183.3 million at December 31, 2024, to $49.9 million at September 30, 2025, primarily due to acquisitions and debt repayments.
• Decrease in net working capital: From $130.0 million at December 31, 2024, to $62.8 million at September 30, 2025.

Risks

• The frequency of work-related injuries and illnesses could adversely impact demand for occupational health services.
• Adverse changes to relationships with employer customers, third-party payors, workers compensation provider networks, or employer services networks.
• Changes to regulations, new interpretations of existing regulations, or violations of regulations could lead to sanctions, damages, or fines.
• State fee schedule changes undertaken by state workers compensation boards or commissions and other third-party payors could impact reimbursement rates.
• Inability to realize reimbursement increases at rates sufficient to keep pace with the inflation of costs.
• Labor shortages, increased employee turnover or costs, and union activity could significantly increase operating costs.
• Inability to compete effectively with other occupational health centers, onsite health clinics at employer worksites, and healthcare providers.
• A security breach of the company's, or its third-party vendors', information technology systems may cause a violation of HIPAA and subject the company to potential legal and reputational harm.
• Negative publicity can result in increased governmental and regulatory scrutiny and possibly adverse regulatory changes.
• Significant legal actions could subject the company to substantial uninsured liabilities.
• Insurance coverage may not be sufficient to cover losses the company may incur.
• Acquisitions may use significant resources, may be unsuccessful, and could expose the company to unforeseen liabilities.
• Exposure to additional risk due to reliance on third parties in many aspects of the business.
• Compliance with applicable laws regarding the corporate practice of medicine and therapy and fee-splitting.
• Facilities are subject to extensive federal and state laws and regulations relating to the privacy of individually identifiable information.
• Compliance with applicable data interoperability and information blocking rules.
• Facility licensure requirements in some states are costly and time-consuming, limiting or delaying operations.
• Inability to adequately protect and enforce intellectual property and other proprietary rights.
• Adverse economic conditions in the U.S. or globally.
• Any negative impact on the global economy and capital markets resulting from other geopolitical tensions.
• The impact of impairment of goodwill and other intangible assets.
• Inability to maintain satisfactory credit ratings.
• The effects of the Separation from Select Medical Corporation on the business.
• Inability to achieve the expected benefits of and successfully execute the Separation and related transactions.
• Restrictions on the business, potential tax and indemnification liabilities, and substantial charges in connection with the Separation and related transactions.
• The negative impact of public threats such as a global pandemic or widespread outbreak of an infectious disease.
• The loss of key members of the management team.
• Inability to attract and retain talented, highly skilled employees and a diverse workforce, and on the succession of senior management.
• Climate change, or legal, regulatory or market measures to address climate change.
• Increasing scrutiny and rapidly evolving expectations from stakeholders regarding ESG matters.
• Changes in tax laws or exposures to additional tax liabilities.
• Changes to United States tariff and import/export regulations and the impact on global economic conditions may have a negative effect on the business, financial condition and results of operations.

Future Outlook

The company intends to grow through strategic acquisitions of existing occupational health centers and onsite health clinic platforms, as well as building new de novo centers. It believes its internally generated cash flows and borrowing capacity under its Revolving Credit Facility will allow it to finance operations in both the short and long term. The company expects to complete its final purchase price allocation for the Nova and Pivot Onsite Innovations acquisitions during the 12-month period subsequent to their closing dates. The company will adopt ASU 2023-09 (Income Taxes) for the annual financial statements ended December 31, 2025, which will impact disclosures but not financial statements. The company is also reviewing the impact of ASU 2024-03 (Expense Disaggregation) and ASU 2025-05 (Credit Losses for Accounts Receivable). The authorized share repurchase program will expire on December 31, 2027, unless extended or terminated. Future dividends are at the discretion of the Board of Directors and subject to various financial and contractual factors.

Management Comments

• We believe our internally generated cash flows and borrowing capacity under our Revolving Credit Facility will allow us to finance our operations in both the short and long term.
• Management believes that the number of patient visits is the single most important indicator of the volume of services being provided in our centers.
• The increase in general and administrative expense as a percentage of revenue is principally due to Nova and Pivot Onsite Innovations acquisition and transition costs, one-time costs to separate from Select, stock compensation expense, and the planned addition of new full-time employees and other personnel costs to support the separation from Select and operate as a standalone public company.

Industry Context

The company is the largest provider of occupational health services in the United States based on the number of locations, operating 628 stand-alone occupational health centers in 41 states and 413 onsite health clinics in 44 states as of September 30, 2025. The acquisitions of Nova Medical Centers and Pivot Onsite Innovations further solidify its market position and expand its reach in occupational health and onsite health clinics. The healthcare industry is labor-intensive, and the company notes that wage and other expenses increase during periods of inflation and labor shortages, though it has experienced minimal inflationary impact thus far. The company operates in a highly regulated environment, subject to federal and state laws regarding corporate practice of medicine, privacy (HIPAA), and billing practices, as evidenced by ongoing legal proceedings.

Legal Proceedings

• California Department of Insurance Investigation: Subpoena received February 5, 2024, relating to an investigation under the California Insurance Frauds Prevention Act concerning billing and coding for physical therapy claims submitted to commercial insurers and workers compensation carriers in California. The company is cooperating but unable to predict timing and outcome.
• Perry Johnson & Associates, Inc. Data Breach: On November 10, 2023, PJ&A (a third-party vendor) notified CHSI of a cybersecurity event. In February 2024, notices were sent to almost four million patients. Six putative class action lawsuits were filed, consolidated into one, alleging negligence, breach of contract, and statutory duty violations (HIPAA, FTC guidelines). The company is working with its cybersecurity risk insurance policy carrier and does not believe it will have a material impact, but timing and outcome are unpredictable.
• Physical Therapy Billing (DOJ/Qui Tam Lawsuit): On October 7, 2021, Select received a letter from the U.S. Department of Justice investigating potential False Claims Act violations related to physical therapy billing. A related qui tam lawsuit was unsealed in May 2024, alleging billing for one-on-one therapy when group therapy was performed, overbilling, and billing for unskilled services. Select's motion to dismiss the second amended complaint was granted in June 2025, but a third amended complaint was filed in July 2025, which Select moved to dismiss in September 2025. The company is unable to predict the timing and outcome.

Related Party Transactions

• Concentra became fully independent on November 25, 2024, after Select Medical Corporation made a special stock distribution. Prior to this, and for some periods in the filing, Select was a related party.
• The company pays fees to Select for shared support functions under a transition services agreement. Fees were $2.7 million (Q3 2025) and $9.9 million (9M 2025), compared to $3.8 million (Q3 2024) and $11.5 million (9M 2024) for shared service/TSA fees.
• No interest expense on related party debt in Q3 2025 or 9M 2025, compared to $2.7 million (Q3 2024) and $22.0 million (9M 2024), due to the payoff of the revolving promissory note with Select in Q3 2024.

Stakeholder Impact

• Shareholders: Benefited from strong revenue and Adjusted EBITDA growth, a new $100 million share repurchase program, and a declared cash dividend of $0.0625 per share. However, diluted EPS decreased for the nine months ended September 30, 2025.
• Employees: Positive impact from planned addition of new full-time employees and restricted stock awards (1.6 million shares, $30.7 million fair value) granted to directors and certain employees. Potential risk from labor shortages or increased costs.
• Customers (Employers/Patients): Benefit from expanded services and locations through strategic acquisitions (Nova, Pivot Onsite Innovations), increasing access to occupational health and onsite health clinics. Potential impact from legal proceedings (e.g., physical therapy billing investigation, data breach) could affect trust or service availability, though the company states no material impact is expected from the data breach lawsuits.
• Creditors: Positive impact from proactive voluntary repayments on the Revolving Credit Facility, reducing outstanding debt. The leverage ratio of 3.6x is well below the covenant limit of 6.5 to 1.0. Hedging strategies mitigate interest rate risk on variable-rate debt. However, there was a significant increase in long-term debt due to acquisitions and refinancing.
• Regulatory Authorities: Ongoing investigations by the California Department of Insurance and the U.S. Department of Justice highlight continuous scrutiny and potential for sanctions or penalties.

Next Steps

• Complete the final purchase price allocation for the Nova and Pivot Onsite Innovations acquisitions within 12 months of their closing dates.
• Adopt ASU 2023-09 (Income Taxes) for the annual financial statements ended December 31, 2025.
• Review the impact of ASU 2024-03 (Expense Disaggregation) and ASU 2025-05 (Credit Losses for Accounts Receivable) on consolidated financial statements.
• Execute the authorized $100 million share repurchase program by December 31, 2027.
• Pay the declared cash dividend of $0.0625 per share on or about December 9, 2025.
• Continue to manage and cooperate with the California Department of Insurance investigation.
• Continue to manage and defend against the consolidated class action lawsuit related to the PJ&A data breach.
• Continue to manage and defend against the qui tam lawsuit related to physical therapy billing.
• Pursue strategic acquisitions of existing occupational health centers and onsite health clinic platforms.
• Build new de novo centers.

Key Dates

Recommendation

Concentra's Q3 2025 results demonstrate robust top-line growth and operational efficiency, with revenue up 17.0% and Adjusted EBITDA up 17.1%. Strategic acquisitions of Nova Medical Centers and Pivot Onsite Innovations significantly expand its market leadership in occupational health and onsite clinics, providing a strong platform for future growth. The company's proactive financial management, including voluntary debt repayments and hedging strategies, strengthens its balance sheet. Furthermore, the authorization of a $100 million share repurchase program and a consistent dividend payout signal confidence from management and a commitment to enhancing shareholder value. While increased interest expenses and general and administrative costs, along with ongoing legal proceedings, present some headwinds, the overall growth trajectory, market position, and shareholder-friendly capital allocation make Concentra an attractive "buy" for long-term investors.

Keywords

Occupational health services, Onsite health clinics, Workers compensation, Employer services, Healthcare provider, SEC filing, 10-Q, Financial results, Acquisitions, Debt financing, Share repurchase, Dividend, CON, Concentra